AstraZeneca PLC
camizestrant
HR-positive breast cancer
Date
TBD
Phase 3 readout · Date TBD estimated
What's at stake
Phase 3 trial results for camizestrant in HR-positive breast cancer are due Date TBD. A clean hit validates the program; a miss can gap the stock down hard.
Primary source
· SEC 6-K
verified 14h ago
“Regulatory applications for camizestrant in this setting are also under review in the EU, Japan and several other countries.”